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Abstract
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are
cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis.
Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing
a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor.
Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who
achieved a clinical and radiological remission with PD-1 blockade.
Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This
warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
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Background
Ewing sarcoma (EWS) is a poorly differentiated, aggressive
malignant small blue round cell tumour of the bone and
soft tissue [1]. It accounts for 34 % of primary bone
tumours in people <20 years with an incidence of 2.9
per million [2]. Conventional treatment for localised
disease is induction multi-agent chemotherapy then
local control with surgery and/or radiation therapy
followed by consolidation chemotherapy [3]. Never-
theless, approximately 30–40 % of patients develop
recurrent local or metastatic disease, which is associ-
ated with a poor prognosis and a 5-year survival of
10–25 % [4–6].
Immune therapy using agents that target the
programmed cell death-1 (PD-1) receptor interaction
via its ligands PD-L1 or PD-L2 has shown efficacy in
patients with advanced melanoma, non-small cell lung
cancer, colorectal cancer, renal cell carcinoma,
Hodgkin lymphoma and other malignancies [7–10]. In
colorectal cancer, clinical response is correlated with
mis-match repair (MMR) deficiency and microsatellite
instability [8, 11]. Genomic instability has been described
in EWS providing a rationale for treatment with immune
checkpoint blockade [12, 13]. To our knowledge, the
patient described here is the first to document the efficacy
of PD-1 blockade in EWS.
Case presentation
Our patient is a 19-year-old male who presented in 2010
with left arm weakness secondary to a left C4-C6 para-
vertebral mass with bony involvement of C6 and T1.
There were no additional sites of disease on a chest CT
and a whole body 18F-FDG PET-CT scan. A CT-guided
core biopsy showed a tumour composed of uniform
small round cells with hyperchromatic round nuclei and
scant cytoplasm (Fig. 1a). The neoplastic cells showed
positive staining in immunostains for CD99 (membranous;
Fig. 1b) and FLI-1 (nuclear) and were negative in immu-
nostains for desmin, myogenin and S-100. Intracytoplasmic
glycogen was demonstrated in a PAS stain. The combined
morphological and immunophenotypic features were
consistent with EWS (the presence of EWSR1 re-
arrangement was confirmed on a subsequent biopsy).
The patient received chemotherapy (vincristine/doxo-
rubicin/cyclophosphamide and ifosfamide/etoposide)
and local intensity modulated radiation therapy
(55Gy/25#) to his mid-cervical spine. At the end of
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treatment, there was no clinical or radiological evidence of
residual or recurrent disease.
Fifteen months after diagnosis, surveillance imaging
identified bony and pulmonary metastatic disease.
Biopsy of a right humeral lesion was morphologically
consistent with recurrent EWS and molecular testing for
the EWSR1 rearrangement was positive. Over the next
4 years, he was treated with multiple chemotherapy
regimens including irinotecan/temozolamide, high-dose
ifosfamide, gemcitabine/docetaxel, a hedgehog signalling
pathway inhibitor (LDE225) and carboplatin/etoposide.
He had palliative radiotherapy to multiple bony sites
including the right humerus, left ilium, thoracic and
lumbar spine and bilateral whole lung radiation with
additional stereotactic therapy to the largest pulmonary
metastases. Over this period, there were short-lived
Fig. 1 a Haematoxylin and eosin stain of primary tumour showing a small round blue cell tumour and b CD99 immunostain of primary tumour
showing positive staining with a membranous pattern
Fig. 2 Coronal 18F-FDG PET-CT scans done prior to (a) and after (b) 3 cycles of pembrolizumab. The markedly increased FDG uptake in the right
side and adjacent soft tissues of T12, in the left ischium and in one of the right middle lobe pulmonary metastases are shown. Post-treatment the
FDG avidity in the bony lesions is much reduced and the right middle lobe lesion had completely resolved
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responses and periods of stable disease but a clinical or
radiological second remission was not achieved.
In May 2015, just over 5 years from diagnosis,
restaging whole body 18F-FDG PET-CT demonstrated
multiple pulmonary metastases and increased FDG
uptake at T11, T12 and the left ischium (Fig. 2a). The
peak standardised uptake value (SUV) in the T12 lesion
was 14.0. Chest CT confirmed 43 nodules of varying
sizes throughout both lung fields (Fig. 3a, c) and
thoracolumbar spine MR imaging demonstrated bony
metastatic disease at T12, L1, L2, L4 and L5 with associ-
ated soft tissue mass at T12/L1 (Fig. 4a, b). He complained
of low back pain but was otherwise asymptomatic with
ECOG performance score of 0.
The patient commenced treatment with pembrolizumab
(Keytruda, MSD) at 2 mg/kg intravenously every 3 weeks.
The first cycle was complicated by fever without an
identified source but there were no other immune-
related adverse events. Restaging after cycle 3 showed
a very good response to therapy with complete reso-
lution of all but 4 of the pulmonary metastases. The
largest nodule in the left lower lobe had reduced in
diameter from 28 to 14 mm and peak SUV was 1.2
compared to 4.3 prior to treatment (Figs. 2b and 3b,
d). The soft tissue component of the lesion at T12
had decreased in size and had a reduction in SUV
from 14 to 6.1 (Figs. 2b and 4c). In addition, there
was resolution of the soft tissue component anteriorly
at L1, reduction in size of the lesion at L2 and better
definition of the lesions at L4 and L5 (Fig. 4c). Clinic-
ally, his back pain resolved. After a further 6 cycles
of pembrolizumab, progress imaging confirmed on-
going response to therapy, with complete resolution
of active pulmonary metastases, a reduction in SUV
at T12 from 6.1 to 4 and stable appearance on MR
imaging (not shown). Treatment was ceased after a
total of 9 cycles and at the most recent review
6 months since the last dose the clinical and radio-
logical response has been sustained.
Discussion
PD-L1 expression has been evaluated in a variety of
sarcomas. The series reported by Raj et al. identified that
39 % of Ewing sarcomas expressed PD-L1 compared
Fig. 3 Coronal chest CTs done prior to (a, c) and after (b, d) 3 cycles of pembrolizumab show a marked decrease in size of the bilobed nodule in
the superior segment of left lower lobe and complete resolution of the smaller left lower lobe nodules
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with 36 % of osteosarcomas and 97 % of leiomyosarco-
mas [14]. Kozak et al. retrospectively analysed 36
tumour samples of patients with synovial sarcoma
and found PD-L1 expression in 83 %, with expression
associated with poorer outcomes [15]. Kim et al.
reported a similar association in a study of soft tissue
sarcomas [16]. Of note, there is evidence across most, but
not all, tumour types of a relationship between PD-L1
expression and response rates to immune checkpoint
blockade, however a lack of PD-L1 expression does not
preclude a response to PD-1 inhibition [7, 17–20]. Despite
the known expression of PD-L1 in sarcoma, the only re-
port of immune checkpoint blockade is a small pilot study
by Maki et al. of the CTLA-4 inhibitor ipilimumab in
advanced synovial sarcoma, in which no objective clinical
responses were seen [21]. Another rationale for the pos-
sible utility of PD-1 blockade in EWS is the presence of
genomic instability [12, 13]. Response to PD-1 blockade in
colorectal cancer has been correlated with MMR
deficiency; however, there are conflicting reports of MMR
status and response in gastric cancer [8, 11, 22].
The explanation for the immune therapy response
in our patient is unclear. Unfortunately, archival
tissue was unavailable and hence we were unable to
correlate response with PD-L1 expression (or lack
of ) in this case. His clinical course was relatively
indolent for metastatic EWS and he had received
extensive prior radiotherapy, which may have height-
ened the immune response. There is emerging evi-
dence to suggest a role for radiotherapy in enhancing
responses to immune therapy through a variety of
mechanisms [23, 24].
Conclusions
To our knowledge, this is the first reported case of
response of EWS to immune checkpoint blockade with
pembrolizumab. The patient’s recurrent metastatic
EWS responded poorly to multiple conventional and
experimental chemotherapeutic agents over the pre-
ceding 4 years, and his early relapse is a well-
recognised poor prognostic marker in recurrent EWS
[4–6, 25]. We suggest that further evaluation of PD-
1-directed therapy in recurrent and metastatic EWS is
warranted and await the results of the SARC028
phase II study investigating efficacy and safety of
pembrolizumab in advanced soft tissue and bone sar-
comas [26]. In addition, evaluation of pre-treatment
and on-treatment biomarkers in SARC028 and future
studies will refine our ability to predict response to
immune checkpoint blockade in individual patients
and monitor treatment efficacy [20, 26].
Fig. 4 Sagittal MR images of thoracolumbar spine: a pre-treatment STIR demonstrates the lesion at T12 with extension through the anterior vertebral
body bony margin; b pre-treatment T2 demonstrates tumour projecting into the T12 prevertebral soft tissue (arrowhead) and into the neural foramen
at L1 (long arrow); and c post 3 cycles of pembrolizumab, there is no longer prevertebral extension of tumour at T12 (arrowhead) and only ill-defined
soft tissue remains around the L1 root (long arrow); lesions in the body of L1, L4 and L5 are also smaller
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